title: Clinical implications of canagliflozin treatment in patients with type 2 diabetes.
abstract: IN BRIEF Sodium glucose cotransporter 2 (SGLT2) inhibitors are a new class of antihyperglycemic agents that lower blood glucose levels in patients with type 2 diabetes. SGLT2 inhibitors have an insulin-independent mechanism of action, acting to inhibit the reabsorption of glucose in the kidney, which leads to increases in urinary glucose excretion in individuals with elevated blood glucose levels. This article provides an overview of the role of the kidney in type 2 diabetes, describes the rationale for renal SGLT2 as a new target for glycemic control, and focuses on the clinical implications of incorporating the SGLT2 inhibitor canagliflozin into type 2 diabetes treatment regimens based on data from phase 3 studies.
authors: Northside Family Medicine, Albuquerque, NM.
authors: Virginia
authors: V
authors: Valentine
authors: Memorial Hospital, Diabetes Center, University of Colorado Health System, Colorado Springs, CO.
authors: Deborah
authors: D
authors: Hinnen
references: Diabetes Obes Metab. 2011 Jul;13(7):669-72
references: 21457428
references: Diabetes Obes Metab. 2012 Jun;14(6):539-45
references: 22226086
references: Pharmacol Ther. 2013 Jul;139(1):51-9
references: 23563279
references: Diabetologia. 2013 Dec;56(12):2582-92
references: 24026211
references: Hosp Pract (1995). 2013 Apr;41(2):72-84
references: 23680739
references: J Diabetes Complications. 2013 Sep-Oct;27(5):479-84
references: 23806570
references: Nat Rev Drug Discov. 2010 Jul;9(7):551-9
references: 20508640
references: Diabetes Care. 2013 Nov;36(11):3396-404
references: 23963895
references: Postgrad Med. 2014 May;126(3):16-34
references: 24918789
references: Diabetes Obes Metab. 2014 May;16(5):467-77
references: 24528605
references: Diabetes. 2012 Jan;61(1):187-96
references: 22124465
references: Diabetes Obes Metab. 2013 Dec;15(12):1154-60
references: 23906374
references: Diabetes. 2009 Apr;58(4):773-95
references: 19336687
references: Endocr Rev. 2011 Aug;32(4):515-31
references: 21606218
references: Diabetes Obes Metab. 2013 May;15(5):463-73
references: 23464594
references: J Clin Endocrinol Metab. 2010 Jan;95(1):34-42
references: 19892839
references: Physiol Rev. 2011 Apr;91(2):733-94
references: 21527736
references: Diabetes Obes Metab. 2013 Apr;15(4):372-82
references: 23279307
references: Diabetes Obes Metab. 2012 Jan;14(1):5-14
references: 21955459
references: Ann Intern Med. 2012 Mar 20;156(6):405-15
references: 22431673
references: Diabetes Obes Metab. 2011 Oct;13(10):928-38
references: 21672123
references: Diabetes Obes Metab. 2009 Dec;11(12):1163-72
references: 19930006
references: Diabetes. 2005 Dec;54(12):3427-34
references: 16306358
references: Lancet. 2013 Sep 14;382(9896):941-50
references: 23850055
references: Diabetes Care. 2013 Sep;36(9):2508-15
references: 23564919
references: Postgrad Med. 2014 Jan;126(1):7-17
references: 24393747
references: Endocrinology. 2008 Feb;149(2):717-24
references: 17962340
references: BMC Pharmacol Toxicol. 2013 May 13;14:26
references: 23668634
references: Diabetes Obes Metab. 2007 Sep;9(5):733-45
references: 17593236
references: Diabetes Care. 2012 Jun;35(6):1232-8
references: 22492586
references: Diabetes Care. 2004 Nov;27(11):2628-35
references: 15504997
references: Int J Clin Pract. 2013 Dec;67(12):1267-82
references: 24118688
references: Endocr Pract. 2013 Mar-Apr;19(2):327-36
references: 23598536
references: Diabetes Care. 2013 Aug;36(8):2154-61
references: 23412078
references: Curr Med Res Opin. 2014 Sep;30(9):1759-68
references: 24786834
references: J Clin Invest. 2014 Feb;124(2):509-14
references: 24463448
references: Curr Diab Rep. 2002 Jun;2(3):231-6
references: 12643178
references: J Diabetes Complications. 2013 Sep-Oct;27(5):473-8
references: 23849632
references: Diabetes Care. 2013 Oct;36(10):3169-76
references: 23735727
references: PLoS One. 2012;7(2):e30555
references: 22355316
references: Curr Med Res Opin. 2014 Jun;30(6):1109-19
references: 24517339
references: Drugs. 2010 Mar 5;70(4):377-85
references: 20205482
references: Curr Med Res Opin. 2014 Feb;30(2):163-75
references: 24073995
references: Diabetes Care. 2005 May;28(5):1083-91
references: 15855571
references: J Clin Invest. 2014 Feb;124(2):499-508
references: 24463454
references: J Clin Pharmacol. 2013 Jun;53(6):601-10
references: 23670707
references: J Clin Invest. 1951 Feb;30(2):125-9
references: 14814204